Investigating how a specific pathway affects the spread of lung cancer lacking a key protein.
Official title: Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-10982146 · Data updated 2026-11-12
This study is looking at how a missing protein in a type of lung cancer affects its ability to spread, and it hopes to find new ways to treat patients by understanding the genetic changes involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $583,127 |
| NIH project number | 1R01CA285856-01A1 |
| Project ID | NIH-10982146 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with SMARCA4-deficient lung adenocarcinoma.
✕Less likely to help
Patients with lung cancer that does not involve SMARCA4 mutations may not benefit from this research.
What this research studies
This research focuses on understanding how the absence of the SMARCA4 protein in lung adenocarcinoma contributes to the cancer's ability to spread to other parts of the body. By examining the ROR2/p-GSK3βS9 pathway, the researchers aim to uncover the mechanisms that drive metastasis in patients with this type of lung cancer. The study employs advanced techniques such as RNA sequencing and chromatin accessibility assays to analyze the genetic changes associated with cancer progression. Patients may benefit from insights that could lead to new therapeutic strategies targeting this pathway.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically inhibit the spread of lung cancer in patients lacking SMARCA4.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Jones, David R — Sloan-Kettering Inst Can Research
- Study coordinator: Jones, David R
Related research
Other NIH-funded projects on the same topics.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
How lung adenocarcinoma spreads and hides from the immune system
This work looks at the specific lung cancer cells that let tumors spread and survive so better ways to prevent relapse can be found.
-
Stopping the spread of lung cancer in patients with a specific gene change
This research aims to find new ways to prevent lung cancer from spreading in patients who have a particular genetic change called SMARCA4 deficiency.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.